A 65-year follow-up study of approximately 7000 multiple sclerosis patients has uncovered that overall, patients are 14% more likely to develop cancer compared to individuals without the disease.
Browsing: Demyelinating disease
A team of researchers have utilized radiocarbon dating to determine that there is little regeneration of oligodendrocytes in the brains of people living with multiple sclerosis. However, the oligodendrocytes that survive the autoimmune attack can replenish lost myelin.
In this interview, we had the pleasure of speaking with Robert Fox about biomarker discovery and development in multiple sclerosis, including serum neurofilament light.
This week we look at gammaCore™ for cluster headache, warnings of stroke risk with a multiple sclerosis drug and a gene therapy for spinal muscular atrophy.
The EMA has approved Gilenya® (fingolimod) for the treatment of children and adolescents with relapsing–remitting forms of multiple sclerosis.
This week we look at NurOwn® for multiple sclerosis, a combination therapy failing to meet primary endpoint for glioblastoma and warnings from the US FDA.
A new cellular immunotherapy that targets the Epsein–Barr virus could improve the symptoms and quality of life for individuals with multiple sclerosis.
At ECTRIMS, we had the pleasure of speaking with Marianna Cortese about her research in multiple sclerosis, including her interest in the microbiome.
In this interview, we spoke with Bruce Trapp about how his team identified a new subtype of multiple sclerosis, termed myelocortical multiple sclerosis.